

EXHIBIT A
CLAIMS WHICH WILL BE PENDING
UPON ENTRY OF THE INSTANT AMENDMENT
(filed February 28, 2001)

U.S. APPLICATION SERIAL NO. 09/724,621
(ATTORNEY DOCKET NO. 9426-056)

18. A method for inhibiting or suppressing viral replication in an animal, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies.

19. A method for inhibiting or suppressing viral replication in an animal, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more viral antigens.

20. A method for inhibiting or suppressing viral replication in an animal, said method comprising administering to the animal a therapeutically effective amount of one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies.

21. A method for inhibiting or suppressing microbial replication in an animal, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies.

22. A method for inhibiting or suppressing microbial replication in an animal, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more microbial antigens.

23. A method for inhibiting or suppressing microbial replication in an animal, said method comprising administering to the animal a therapeutically effective amount of one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies.

24. The method of claim 18, 19, 21 or 22 further comprising administering to the animal IgG enriched plasma.

25. The method of claim 18, 19, 21 or 22 further comprising administering to the animal IgM enriched plasma.

26. The method of claim 24 further comprising administering to the animal IgM enriched plasma.

27. The method of claim 18, 19, 21 or 22 further comprising administering to the animal one or more complement components.

28. The method of claim 20 further comprising administering to the animal one or more nucleic acid sequences encoding one or more complement components.

29. The method of claim 20 or 28 further comprising administering to the animal one or more nucleic acid sequences encoding one or more antibodies immunospecific for one or more viral antigens.

30. The method of claim 23 further comprising administering to the animal one or more nucleic acid sequences encoding one or more complement components.

31. The method of claim 23 or 30 further comprising administering to the animal one or more nucleic acid sequences encoding one or more nucleic acid sequences encoding one or more antibodies immunospecific for one or more microbial antigens.

32. A method for treating septic shock in an animal, said method comprising administering to the animal one or more anti-C3b(i) antibodies.

33. The method of claim 18, 19, 21, 22 or 32, wherein at least one of the anti-C3b(i) antibodies is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.

34. The method of claim 18, 19, 21, 22 or 32, wherein at least one of the anti-C3b(i) antibodies is a monoclonal antibody.

35. The method of claim 34, wherein the monoclonal antibody is a human or humanized antibody.

36. The method of claim 33 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer or erythrocyte.

37. The method of claim 33 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64 or CD89.

38. The method of claim 18, 19, 21, 22 or 32 in which at least one of anti-C3b(i) antibodies is conjugated to a therapeutic agent.

39. The method of claim 18, 19, 20, 21, 22, 23 or 32 in which the animal is a mammal.

40. The method of claim 18, 19, 20, 21, 22, 23 or 32 in which the animal is a human.

41. The method of claim 18, 19 or 20, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to IgM or IgG antibody bound to a virus.

42. The method of claim 18, 19 or 20, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to a viral antigen.

43. The method of claim 21, 22 or 23, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to IgM or IgG antibody bound to a microbe.

44. The method of claim 21, 22 or 23, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to a microbial antigen.

45. The method of claim 32, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to lipopolysaccharide.

46. The method of claim 42 in which at least one of the viral antigens is HIV gp120 or RSV F glycoprotein.

47. The method of claim 44 in which at least one of the microbial antigens is lipopolysaccharide.

48. The method of claim 18, 19 or 20 in which the viral infection is caused by a retrovirus, a herpes virus, an arenavirus, a paramyxovirus, an adenovirus, a bunyavirus, a coronavirus, a filovirus, a flavivirus, a hepadnavirus, an orthomyovirus, a papovavirus, a picornavirus, a poxvirus, a reovirus, a togavirus, or a rhabdovirus.

49. The method of claim 21, 22 or 23 in which the microbial infection is a yeast infection, fungal infection, protozoan infection or bacterial infection.

50. The method of claim 49 in which the bacterial infection is caused by *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter (Vibrio) fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema pallidum*, *Treponema pertenue*, *Treponema caratenum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma spp.*, *Rickettsia prowazekii*, *Rickettsia tsutsugumushi*, *Chlamydia spp.*, or *Helicobacter pylori*.